한글목차

세계 암성 통증 시장은 방사선 치료, 화학요법, 호르몬 요법 시장에서 기회가 있으며, 미래가 기대되는 시장입니다. 세계 암성 통증 시장은 2025-2031년 5.1%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 종양 크기 증가와 주변 조직에 대한 압박, 다른 장기로의 암 전이 증가입니다.

• Lucintel의 예측에 따르면, 유형별로는 오피오이드가 예측 기간 동안 높은 성장세를 보일 것으로 예측됩니다.
• 용도별로는 화학요법이 가장 높은 성장이 예상됩니다.
• 지역별로는 APAC 지역이 예측 기간 동안 가장 높은 성장을 보일 것으로 예측됩니다.

150페이지가 넘는 방대한 분량의 이 보고서는 비즈니스 의사결정에 도움이 되는 귀중한 통찰력을 제공합니다. 다음은 몇 가지 통찰력을 담은 샘플 다이어그램입니다.

암성 통증 시장의 새로운 트렌드

암성 통증 시장의 신흥 동향은 치료법 개발, 제공 및 접근 방식을 형성하고 있습니다. 이러한 추세는 보다 효과적이고 개인화된, 접근하기 쉬운 통증 관리 솔루션에 대한 요구가 증가하고 있음을 반영합니다. 제약 연구 혁신, 기술 발전, 환자 치료의 변화가 시장의 진화를 촉진하고 있습니다. 다음은 암 통증 관리의 전망을 바꾸고 있는 5가지 주요 트렌드입니다.

• 오피오이드 대체약물 및 비약물 요법: 오피오이드 의존성 및 부작용에 대한 우려가 커지면서 암성 통증 관리에서 비오피오이드 대체요법으로의 전환이 이루어지고 있습니다. 여기에는 가바펜티노이드, 항우울제 등의 약물 치료와 침술, 물리치료, 인지행동치료 등의 비약물 치료가 포함됩니다. 이러한 치료는 오피오이드에 수반되는 위험 없이 효과적인 진통 효과를 제공하는 것을 목표로 합니다.
• 개별화된 통증 관리: 환자의 통증 경험과 치료에 대한 반응은 천차만별이기 때문에 개별화된 통증 관리는 중요한 트렌드가 되고 있습니다. 첨단 진단 도구와 유전자 프로파일링을 통해 임상의들은 환자 개개인의 필요에 따라 맞춤형 치료를 할 수 있게 되었습니다. 개별화된 접근법은 통증 완화를 개선하고 부작용을 최소화하며, 암성 통증에 대한 보다 표적화되고 효과적인 솔루션을 제공할 것으로 기대됩니다.
• 약물 전달의 혁신 : 경피흡수 패치, 서방형 제제, 마이크로 캡슐화 기술 등 새로운 약물 전달 시스템은 암성 통증 관리에 혁명을 일으키고 있습니다. 이러한 기술 혁신은 지속적인 통증 완화를 가능하게 하고, 잦은 투약의 필요성을 줄여 환자의 편의성을 향상시키고 있습니다. 또한, 이러한 첨단 시스템은 진통제의 혈중 농도를 안정화하여 진통제의 효과와 환자 결과를 개선하는 데 도움이 됩니다.
• 완화의료에 대한 관심 증가: 전 세계적으로 암 진단이 증가함에 따라 통증 관리를 핵심으로 하는 완화의료에 대한 관심이 높아지고 있습니다. 완화의료는 신체적 고통뿐만 아니라 정서적, 심리적, 사회적 요구에 대응하여 환자의 삶의 질을 향상시키는 것을 목적으로 합니다. 의료 제공업체와 정책 입안자들은 암 환자의 복잡한 요구에 대응하기 위해 완화의료 프로그램 및 서비스 개발에 우선순위를 두고 있습니다.
• 재택 치료로의 전환: 재택 치료는 암성 통증 관리에서 점점 더 많은 추진력을 얻고 있습니다. 원격 의료, 재택치료 서비스, 휴대용 통증 관리 기기의 발전으로 환자들은 집에서 효과적인 치료를 받을 수 있게 되었습니다. 이러한 변화는 입원 기간을 단축하고, 의료비를 절감하며, 환자가 치료 중에도 집에서 편안하게 지낼 수 있어 전반적인 환자 만족도와 삶의 질을 향상시킬 수 있습니다.

이러한 추세는 보다 다양하고 개인화된 솔루션을 제공함으로써 암성통증 시장을 재편하고 있습니다. 오피오이드에서 벗어나고, 약물 전달 기술의 발전, 전인적 치료에 대한 관심은 환자의 결과와 만족도를 향상시키고 있습니다. 또한, 재택 및 완화의료 모델로의 전환은 전 세계적으로 증가하는 암 부담에 대처하는 데 있어 매우 중요한 접근성과 경제성을 높이고 있습니다.

암성 통증 시장의 최근 동향

암성 통증 시장은 기술 발전, 혁신적인 치료법, 진화하는 의료 정책으로 인해 큰 변화를 겪고 있습니다. 이러한 발전은 암성 통증의 관리를 강화하고 효과적인 치료에 대한 접근성을 확대하는 데 기여하고 있습니다. 다음은 암성 통증 시장의 성장과 방향성에 영향을 미치는 5가지 주요 발전입니다.

• 비오피오이드 기반 통증 관리 옵션 개발: 오피오이드 사용에 따른 위험성에 대한 인식이 높아지면서 오피오이드를 사용하지 않는 통증 관리 옵션이 개발되고 있습니다. 이러한 대체 약물로는 신경차단술, 신경성장인자 억제제, 칸나비노이드 등이 있으며, 부작용이 적고 효과적인 진통 효과를 제공합니다. 이러한 대안으로의 전환은 오피오이드 의존도를 낮추고 암 환자의 통증 관리 전반을 개선할 수 있을 것으로 기대됩니다.
• 통증 관리 기기의 발전: 기술 혁신으로 신경자극기, 척수자극기 등 첨단 통증 관리 기기가 개발되고 있습니다. 이 기기들은 난치성 암성 통증 치료에 사용되고 있으며, 환자들에게 기존 약물 치료 이상의 선택권을 제공합니다. 이러한 기기의 보급은 통증 관리에 대한 개인화된 접근 방식에 기여하고 있습니다.
• 통증 관리 접근성 규제 개선: 미국과 유럽을 포함한 일부 지역에서는 암성 통증 관리 솔루션에 대한 접근성을 개선하기 위한 규제 개혁이 시행되고 있습니다. 오피오이드에 대한 접근성 확대, 새로운 비오피오이드 치료법 승인, 상환제도 강화에 중점을 둔 정책으로 환자들이 필요한 치료를 더 쉽게 받을 수 있게 되었습니다.
• 병용요법의 혁신 : 약리학적 치료와 비약리학적 개입을 결합한 병용요법이 활성화되고 있습니다. 이러한 치료법은 암성 통증의 여러 측면을 다루며, 환자에게 보다 종합적인 치료 옵션을 제공합니다. 예를 들어, 오피오이드 약물과 침술이나 물리치료를 병행하면 통증 완화를 강화하고 삶의 질을 향상시킬 수 있습니다.
• 통증 관리에 원격의료의 통합: 원격의료는 의료진이 원격으로 환자를 모니터링하고 치료 계획을 실시간으로 조정할 수 있게 함으로써 암 통증 관리에 변화를 가져오고 있습니다. 이 개발은 특히 지방이나 의료서비스가 부족한 지역의 환자들에게 도움이 될 것이며, 통증 관리를 보다 쉽게 할 수 있게 해줄 것입니다. 원격 의료의 통합은 또한 환자의 치료 참여와 순응도를 향상시킵니다.

이러한 주요 발전은 보다 효과적이고 개인화된, 접근하기 쉬운 치료법을 제공함으로써 암성 통증 관리의 상황을 개선하고 있습니다. 그 결과, 환자는 더 나은 통증 완화와 삶의 질 향상을 경험하고, 의료 시스템은 보다 비용 효율적인 솔루션의 혜택을 누리고 있습니다.

목차

제1장 주요 요약

제2장 세계의 암성 통증 시장 : 시장 역학

• 서론, 배경 및 분류
• 공급망
• PESTLE 분석
• 특허 분석
• 규제 환경
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019년-2024년)과 예측(2025년-2031년)
• 세계의 암성 통증 시장 동향(2019년-2024년)과 예측(2025년-2031년)
• 세계의 암성 통증 시장 : 유형별
  • 오피오이드 : 동향과 예측(2019-2031년)
  • 비스테로이드성 항염증제 : 동향과 예측(2019-2031년)
  • 기타 : 동향과 예측(2019-2031년)
• 세계의 암성 통증 시장 : 용도별
  • 방사선 치료 : 동향과 예측(2019-2031년)
  • 화학 요법 : 동향과 예측(2019-2031년)
  • 호르몬 요법 : 동향과 예측(2019-2031년)
  • 기타 : 동향과 예측(2019-2031년)

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 지역별 세계의 암성 통증 시장
• 북미의 암성 통증 시장
• 유럽의 암성 통증 시장
• 아시아태평양의 암성 통증 시장
• 기타 지역의 암 통증 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 바이어의 교섭력
  • 공급 기업의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 암성 통증 시장 유형별 성장 기회
  • 세계의 암성 통증 시장 용도별 성장 기회
  • 지역별 세계의 암성 통증 시장 성장 기회
• 세계 암성 통증 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 암성 통증 시장 캐파시티 확대
  • 세계 암성 통증 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 주요 기업 개요

• BioDelivery Science
• ProStrakan Group
• Teva Pharmaceuticals
• Eli-Lilly
• Grunenthal Group
• GW Pharmaceuticals
• Johnson&Johnson
• Meda Pharmaceuticals
• Orexo
• Sanofi

영문목차

The future of the global cancer pain market looks promising with opportunities in the radiotherapy, chemotherapy, and hormone therapy markets. The global cancer pain market is expected to grow with a CAGR of 5.1% from 2025 to 2031. The major drivers for this market are increase in tumor size and pressure on surrounding tissues and the rising spread of cancer to other organs causes.

• Lucintel forecasts that, within the type category, opioids are expected to witness higher growth over the forecast period.
• Within the application category, chemotherapy is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.

Emerging Trends in the Cancer Pain Market

Emerging trends in the cancer pain market are shaping the way treatments are developed, delivered, and accessed. These trends reflect the growing need for more effective, personalized, and accessible pain management solutions. Innovations in pharmaceutical research, technological advancements, and shifts in patient care are driving the evolution of the market. Below are five key trends that are transforming the landscape of cancer pain management.

• Opioid Alternatives and Non-Pharmacological Therapies: With growing concerns about opioid dependence and side effects, there is an increasing shift towards non-opioid alternatives for cancer pain management. These include medications such as gabapentinoids and anti-depressants, as well as non-pharmacological approaches like acupuncture, physiotherapy, and cognitive-behavioral therapy. These treatments aim to provide effective pain relief without the risks associated with opioids.
• Personalized Pain Management: Personalized pain management is becoming a significant trend, as patients' pain experiences and responses to treatments vary greatly. Advanced diagnostic tools and genetic profiling are enabling clinicians to tailor treatments based on individual needs. Personalized approaches are expected to improve pain relief and minimize side effects, offering more targeted and effective solutions for cancer pain.
• Technological Innovations in Drug Delivery: New drug delivery systems, such as transdermal patches, slow-release formulations, and microencapsulation technologies, are revolutionizing cancer pain management. These innovations allow for continuous pain relief, reducing the need for frequent dosing and enhancing patient convenience. Furthermore, these advanced systems can help maintain stable blood levels of pain relief medications, improving efficacy and patient outcomes.
• Growing Palliative Care Focus: As cancer diagnoses increase globally, there is an expanding focus on palliative care, which includes pain management as a core component. Palliative care aims to improve the quality of life for patients by addressing not only physical pain but also emotional, psychological, and social needs. Healthcare providers and policymakers are prioritizing the development of palliative care programs and services to address the complex needs of cancer patients.
• Shift toward Home-based Care: Home-based care is gaining momentum in cancer pain management. Advances in telemedicine, home healthcare services, and portable pain management devices are enabling patients to receive effective treatment in their homes. This shift reduces hospital stays, lowers healthcare costs, and provides patients with the comfort of being at home during their treatment, improving overall patient satisfaction and quality of life.

These trends are reshaping the cancer pain market by offering more diversified and personalized solutions. The move away from opioids, advancements in drug delivery technologies, and the focus on holistic care are improving patient outcomes and satisfaction. Additionally, the shift to home-based and palliative care models is increasing accessibility and affordability, which is crucial for addressing the growing global cancer burden.

Recent Developments in the Cancer Pain Market

The cancer pain market is undergoing significant changes driven by technological advancements, innovative therapies, and evolving healthcare policies. These developments are enhancing the management of cancer pain and expanding access to effective treatments. Below are five key developments in the cancer pain market that are influencing its growth and direction.

• Development of Non-Opioid Pain Management Options: The increasing awareness of the risks associated with opioid use has led to the development of non-opioid pain management alternatives. These alternatives include nerve block treatments, nerve growth factor inhibitors, and cannabinoids, offering effective pain relief with fewer side effects. The shift to these options is expected to reduce opioid dependence and improve overall pain management for cancer patients.
• Advancements in Pain Management Devices: Technological innovations have resulted in the development of advanced pain management devices, such as neurostimulation and spinal cord stimulators. These devices are being used to treat refractory cancer pain and offer patients more options beyond traditional drug therapies. The growing popularity of these devices is contributing to a more personalized approach to pain management.
• Regulatory Improvements in Pain Management Access: In several regions, including the United States and Europe, regulatory changes are being implemented to improve access to cancer pain management solutions. Policies focusing on expanding opioid access, approving new non-opioid therapies, and enhancing reimbursement mechanisms are making it easier for patients to access the treatments they need.
• Innovations in Combination Therapies: The trend toward combination therapies, which combine pharmacological treatments with non-pharmacological interventions, is gaining momentum. These therapies address multiple aspects of cancer pain and provide patients with more comprehensive treatment options. For example, combining opioid medications with acupuncture or physical therapy can enhance pain relief and improve quality of life.
• Integration of Telemedicine in Pain Management: Telemedicine is transforming cancer pain management by allowing healthcare providers to monitor patients remotely and provide real-time adjustments to treatment plans. This development is particularly beneficial for patients in rural or underserved areas, making pain management more accessible. The integration of telemedicine also improves patient engagement and compliance with treatment regimens.

These key developments are enhancing the cancer pain management landscape by providing more effective, personalized, and accessible treatment options. As a result, patients are experiencing better pain relief and improved quality of life, while healthcare systems benefit from more cost-effective solutions.

Strategic Growth Opportunities in the Cancer Pain Market

The cancer pain market offers significant growth opportunities, particularly in response to the growing global incidence of cancer and the evolving needs of patients. Key applications such as pharmaceuticals, medical devices, and palliative care are critical areas where strategic growth can be achieved. Below are five key growth opportunities by application that are shaping the future of cancer pain management.

• Pharmaceutical Advancements: The development of new pain-relief medications, particularly non-opioid analgesics, presents significant growth opportunities. With increasing concerns over opioid misuse, pharmaceutical companies are focusing on alternatives such as cannabinoids, anti-depressants, and local anesthetics. Innovations in these medications could provide more effective and safer options for managing cancer pain.
• Medical Devices for Pain Management: The medical devices segment, including transdermal drug delivery systems, neurostimulation, and implantable pumps, is seeing rapid growth. These devices allow for targeted pain relief, reducing side effects and improving patient quality of life. As technology improves, there will be further opportunities to develop more efficient and user-friendly devices for cancer pain management.
• Palliative Care Programs: With the rising demand for compassionate care, there is a growing opportunity to develop comprehensive palliative care programs. These programs not only focus on pain management but also address the emotional, psychological, and spiritual needs of cancer patients. Investment in such programs can help healthcare providers offer holistic care, improving patient outcomes and satisfaction.
• Telemedicine and Home Care Solutions: The expansion of telemedicine and home-based care services presents an opportunity to reach more patients with cancer pain, especially those in remote or underserved areas. By offering remote consultations and monitoring, healthcare providers can deliver continuous care, ensuring timely adjustments to pain management treatments.
• Oncology-focused Pain Clinics: Specialized oncology pain clinics are emerging as a key opportunity for growth. These clinics provide expert, multi-disciplinary care to cancer patients suffering from pain, offering tailored treatments that address the complexity of cancer pain. The rise in such specialized clinics is an important trend in providing comprehensive care.

These growth opportunities are reshaping the cancer pain market by enhancing access to more personalized, effective, and holistic treatment options. The focus on innovation in drugs, devices, palliative care, and telemedicine is improving patient outcomes and satisfaction while opening new avenues for market expansion.

Cancer Pain Market Driver and Challenges

The cancer pain market is driven by a variety of technological, economic, and regulatory factors, but it also faces several challenges that impact its growth. Understanding the key drivers and challenges is crucial for stakeholders in the healthcare industry to navigate and capitalize on market opportunities. Below are the main drivers and challenges impacting the cancer pain market.

The factors responsible for driving the cancer pain market include:

1. Technological Advancements: New technologies in drug delivery systems, pain management devices, and diagnostic tools are transforming the cancer pain market. Innovations such as personalized pain management and neurostimulation devices are driving market growth by providing more targeted and effective treatments for cancer pain.

2. Increasing Cancer Prevalence: The rising global incidence of cancer is a major driver of the cancer pain market. As the number of cancer patients increases, so does the demand for pain management solutions. This trend is particularly prominent in aging populations, where cancer-related pain management becomes an even more critical need.

3. Opioid Crisis and Shift to Non-Opioid Alternatives: The growing concerns over opioid misuse and addiction are driving the demand for non-opioid alternatives for cancer pain relief. This shift is encouraging research and development in non-opioid medications, as well as alternative pain management therapies such as nerve blocks and acupuncture.

4. Healthcare System Advancements: Improvements in healthcare infrastructure and cancer care policies in both developed and emerging markets are enabling better access to cancer pain management solutions. This includes better insurance coverage, reimbursement policies, and government support for cancer care services.

5. Rising Patient Awareness and Demand for Better Pain Management: Increased awareness among patients and healthcare providers about the importance of managing cancer pain has led to higher demand for effective treatments. This demand is driving innovation in pain management strategies and fueling market growth.

Challenges in the cancer pain market are:

1. Access to Opioids and Pain Management in Developing Regions: Limited access to opioids and other pain management therapies in developing regions remains a significant challenge. Regulatory restrictions, supply chain issues, and cultural stigmas around pain management hinder the ability of patients in these regions to receive adequate care.

2. High Treatment Costs: The high cost of advanced pain management therapies, including certain medications and medical devices, remains a barrier for many patients, especially in low-income and middle-income countries. This limits the affordability and accessibility of effective cancer pain treatments.

3. Lack of Awareness in Rural Areas: In many parts of the world, particularly rural areas, there is a lack of awareness about cancer pain management options. This results in underdiagnosis and undertreatment of cancer pain, negatively impacting patient outcomes.

The cancer pain market is experiencing rapid growth driven by technological innovations, increasing cancer prevalence, and the shift toward non-opioid pain management. However, challenges such as access to treatments in developing regions, high treatment costs, and lack of awareness remain key barriers to market expansion. Addressing these challenges will be crucial for ensuring that cancer patients worldwide receive effective pain management.

List of Cancer Pain Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer pain companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer pain companies profiled in this report include-

• BioDelivery Science
• ProStrakan Group
• Teva Pharmaceuticals
• Eli-Lilly
• Grunenthal Group
• GW Pharmaceuticals
• Johnson&Johnson
• Meda Pharmaceuticals
• Orexo
• Sanofi

Cancer Pain Market by Segment

The study includes a forecast for the global cancer pain market by type, application, and region.

Cancer Pain Market by Type [Value from 2019 to 2031]:

• Opioids
• Non-Steroidal Anti-Inflammatory Drugs
• Others

Cancer Pain Market by Application [Value from 2019 to 2031]:

• Radiotherapy
• Chemotherapy
• Hormone Therapy
• Others

Cancer Pain Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Cancer Pain Market

Cancer pain is a significant issue for cancer patients worldwide, with many facing both acute and chronic pain as a result of the disease and its treatments. The market for cancer pain management includes various therapies, including pharmaceutical options, medical devices, and alternative treatments. Over the years, advancements in drug formulations, the introduction of innovative therapies, and the growing awareness around cancer pain management have propelled the market forward. This document explores the key recent developments, emerging trends, growth opportunities, and the drivers and challenges affecting the cancer pain market in different regions, including the United States, China, Germany, India, and Japan.

• United States: The United States has seen significant advancements in the cancer pain market, with increased adoption of new drug formulations and the development of innovative pain management technologies. Key players in the pharmaceutical sector are focusing on improving opioid alternatives to address both efficacy and safety concerns. Non-opioid pain management strategies, such as the use of cannabinoids, nerve blocks, and personalized treatments, are gaining traction. Additionally, regulatory efforts and reimbursement policies have improved access to pain relief for cancer patients, fostering market growth.
• China: The Chinese cancer pain market is experiencing rapid growth, driven by the country's increasing cancer incidence and healthcare advancements. New analgesic drugs, particularly opioid and non-opioid alternatives, are becoming more widely available. The government's focus on improving healthcare infrastructure and enhancing cancer care services is helping address pain management needs. However, there are still challenges in reaching underserved rural areas and overcoming cultural stigmas surrounding pain management. Overall, the Chinese market is witnessing a growing demand for pain relief solutions as awareness of cancer pain treatment expands.
• Germany: The German cancer pain market is characterized by high-quality healthcare services and the widespread adoption of advanced treatment options. The country has seen a rise in the use of multi-modal pain management strategies, including pharmacological and non-pharmacological treatments. The increasing preference for targeted therapies and combination therapies for cancer pain has influenced market growth. The government's strong regulatory frameworks and comprehensive insurance systems have also helped improve access to pain management services, contributing to the overall growth of the market.
• India: The Indian cancer pain market is evolving due to a rising cancer burden and improved healthcare access, especially in urban areas. While the market faces challenges such as opioid access restrictions and insufficient awareness, there have been notable advancements in pain management through the use of non-opioid alternatives, such as nerve blocks and palliative care programs. The development of low-cost generic analgesics is helping make cancer pain management more affordable. Furthermore, increased focus on healthcare policy reforms and infrastructure improvements is expected to accelerate the growth of the market in India.
• Japan: Japan is witnessing steady growth in the cancer pain management market, driven by the aging population and advancements in medical technology. There is a strong focus on improving personalized cancer care, with new drug delivery systems, including slow-release formulations, being developed for long-term pain management. The government is also investing in expanding palliative care services and supporting research into alternative pain management options, such as non-pharmacological therapies. The Japanese market's growth is also fueled by an increased public and healthcare provider awareness about cancer pain.

Features of the Global Cancer Pain Market

• Market Size Estimates: Cancer pain market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Cancer pain market size by type, application, and region in terms of value ($B).
• Regional Analysis: Cancer pain market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the cancer pain market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer pain market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cancer pain market by type (opioids, non-steroidal anti-inflammatory drugs, and others), application (radiotherapy, chemotherapy, hormone therapy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Pain Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: PESTLE Analysis
• 2.4: Patent Analysis
• 2.5: Regulatory Environment
• 2.6: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Cancer Pain Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Cancer Pain Market by Type
  • 3.3.1: Opioids: Trends and Forecast (2019 to 2031)
  • 3.3.2: Non-Steroidal Anti-Inflammatory Drugs: Trends and Forecast (2019 to 2031)
  • 3.3.3: Others: Trends and Forecast (2019 to 2031)
• 3.4: Global Cancer Pain Market by Application
  • 3.4.1: Radiotherapy: Trends and Forecast (2019 to 2031)
  • 3.4.2: Chemotherapy: Trends and Forecast (2019 to 2031)
  • 3.4.3: Hormone Therapy: Trends and Forecast (2019 to 2031)
  • 3.4.4: Others: Trends and Forecast (2019 to 2031)

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Cancer Pain Market by Region
• 4.2: North American Cancer Pain Market
  • 4.2.1: North American Market by Type: Opioids, Non-Steroidal Anti-Inflammatory Drugs, and Others
  • 4.2.2: North American Market by Application: Radiotherapy, Chemotherapy, Hormone Therapy, and Others
  • 4.2.3: The United States Cancer Pain Market
  • 4.2.4: Mexican Cancer Pain Market
  • 4.2.5: Canadian Cancer Pain Market
• 4.3: European Cancer Pain Market
  • 4.3.1: European Market by Type: Opioids, Non-Steroidal Anti-Inflammatory Drugs, and Others
  • 4.3.2: European Market by Application: Radiotherapy, Chemotherapy, Hormone Therapy, and Others
  • 4.3.3: German Cancer Pain Market
  • 4.3.4: French Cancer Pain Market
  • 4.3.5: Spanish Cancer Pain Market
  • 4.3.6: Italian Cancer Pain Market
  • 4.3.7: The United Kingdom Cancer Pain Market
• 4.4: APAC Cancer Pain Market
  • 4.4.1: APAC Market by Type: Opioids, Non-Steroidal Anti-Inflammatory Drugs, and Others
  • 4.4.2: APAC Market by Application: Radiotherapy, Chemotherapy, Hormone Therapy, and Others
  • 4.4.3: Japanese Cancer Pain Market
  • 4.4.4: Indian Cancer Pain Market
  • 4.4.5: Chinese Cancer Pain Market
  • 4.4.6: South Korean Cancer Pain Market
  • 4.4.7: Indonesian Cancer Pain Market
• 4.5: ROW Cancer Pain Market
  • 4.5.1: ROW Market by Type: Opioids, Non-Steroidal Anti-Inflammatory Drugs, and Others
  • 4.5.2: ROW Market by Application: Radiotherapy, Chemotherapy, Hormone Therapy, and Others
  • 4.5.3: Middle Eastern Cancer Pain Market
  • 4.5.4: South American Cancer Pain Market
  • 4.5.5: African Cancer Pain Market

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Cancer Pain Market by Type
  • 6.1.2: Growth Opportunities for the Global Cancer Pain Market by Application
  • 6.1.3: Growth Opportunities for the Global Cancer Pain Market by Region
• 6.2: Emerging Trends in the Global Cancer Pain Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Cancer Pain Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Pain Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: BioDelivery Science
  • Company Overview
  • Cancer Pain Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.2: ProStrakan Group
  • Company Overview
  • Cancer Pain Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.3: Teva Pharmaceuticals
  • Company Overview
  • Cancer Pain Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.4: Eli-Lilly
  • Company Overview
  • Cancer Pain Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.5: Grunenthal Group
  • Company Overview
  • Cancer Pain Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.6: GW Pharmaceuticals
  • Company Overview
  • Cancer Pain Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.7: Johnson&Johnson
  • Company Overview
  • Cancer Pain Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.8: Meda Pharmaceuticals
  • Company Overview
  • Cancer Pain Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.9: Orexo
  • Company Overview
  • Cancer Pain Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 7.10: Sanofi
  • Company Overview
  • Cancer Pain Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing